Business Wire

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, ...
Business Wire

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts ...
Seeking Alpha

Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy

Pfizer (PFE) on Saturday reported detailed results from several mid-stage trials, noting that its obesity therapy, berobenatide (PF’3944), added from its Metsera acquisition last year, could become ...
Morningstar

Pfizer: Solid Midstage Danuglipron Data in Diabetes and Weight Loss Supports Continued Development

Pfizer PFE published solid and detailed phase 2 data on diabetes and weight loss drug danuglipron largely in line with our expectations. We don’t expect any major changes to our fair value estimate or ...